3种方案治疗反流性食道炎的成本-效果分析  

Cost-effectiveness Analysis of 3 Therapeutic Regimes for Reflux Esophagitis

作　　者：张惠卿[1] 李梅[1] 尹逊香 

机构地区：[1]山东省潍坊市人民医院药剂科,山东潍坊261041 [2]山东省泰安市肥城石横医院,山东泰安271621

出　　处：《中国药业》2007年第21期43-44,共2页China Pharmaceuticals

摘　　要：目的评价反流性食道炎3种治疗方案的成本-效果分析结果。方法将125例患者随机分成3组,A组服用枸橼酸莫沙必利片,B组服用枸橼酸莫沙必利片加铝碳酸镁片,C组服用枸橼酸莫沙必利片加法莫替丁,治疗4周观察疗效,并进行成本-效果分析。结果A,B,C组治疗成本分别为1092.68,1321.16,1107.24元;有效率分别为53.49%,73.81%,87.50%;成本-效果比分别为20.43,17.90,12.65;B组和C组相对于A组的增量成本-效果比分别为11.24和0.43。结论口服枸橼酸莫沙必利片加法莫替丁是治疗反流性食道炎的较佳治疗方案。Objective To evaluate the cost- effectiveness of 3 therapeutic regimes in the treatment of reflux esophagitis. Methods 125 cases were randomly divided into 3 groups. Group A was treated with mosapride citrate tablet, group B with mosapride citrate tablet plus hydrotalcite tablet, and group C with mosapride citrate tablet plus famotidine. The curative effects of 3 groups were observed after oral administration and the cost-effectiveness analysis was conducted as well. Results The costs for group A, B and C were 1 092. 68 yuan, 1 321.16 yuan and 1 107.24 yuan, respectively. The effective rates were 53.49% ,73.81% and 87.50%, respectively. The cost-effectiveness ratio were 20.43, 17.90 and 12.65, respectively. The incremental cost-effectiveness ratios for group B and C vs group A were 11.24 and 0. 43, respectively. Conclusion Regimen C was superior to other two therapeutic regimes.

关 键 词：反流性食道炎 治疗方案 成本-效果分析 药物经济学 

分 类 号：F407.7[经济管理—产业经济] R969.3[医药卫生—药理学]